Physician profile
Brian Shin
NPI 1265094247
$805.21
in general payments reported to CMS, 2019-2025
12 companies · $742 in 2025
The $742 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $63.67 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $154.61 | 2025 | Airsupra, Farxiga |
| Kowa Pharmaceuticals America, INC. | $120.25 | 2025 | Zoryve |
| Novo Nordisk INC | $119.76 | 2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $84.79 | 2024-2025 | |
| Abiomed | $77.70 | 2025 | |
| Exact Sciences Corporation | $59.85 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $55.80 | 2024-2025 | Otezla, Repatha, Otezla |
| Dexcom, INC. | $52.34 | 2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $23.65 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lilly USA, LLC | $22.19 | 2025 | Mounjaro |
| Pfizer INC. | $19.38 | 2025 | |
| Glaxosmithkline, LLC. | $14.89 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.